Imprimis introduces new treatment for glaucoma

Glaucoma makes up a huge portion of the opthalmic market in the U.S.
Glaucoma makes up a huge portion of the opthalmic market in the U.S. | File photo

Imprimis Pharmaceutical Inc. launch its new Simple drops glaucoma drops at the American Society of Cataract and Refractive Surgery 2017 meeting at the Los Angeles Convention Center this month.

"We believe our Simple drops portfolio gives us a unique advantage in the marketplace because they have been design to help improve compliance by reducing the number of drops patients administer daily," Imprimis CEO Mark Baum said.

Glaucoma makes up a huge portion of the opthalmic market in the U.S., over $2 billion annually.

Baum said the internal team of sales managers would be collaborating with Precision Labs, in the hopes of distributing the treatment throughout the Midwest.

Want to get notified whenever we write about Imprimis Pharmaceuticals, Inc. ?
Next time we write about Imprimis Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Imprimis Pharmaceuticals, Inc. 12264 El Camino Real San Diego, CA - 92130